Plasminogen activator inhibitor-1 and susceptibility to lung cancer: a population genetics perspective

Basit Öğe Kaydı
dc.authorid0000-0001-8567-807Xen_US
dc.authorid0000-0002-7261-6790en_US
dc.contributor.authorBayramoğlu, Ayşegül
dc.contributor.authorGüneş, Hasan Veysi
dc.contributor.authorMetintaş, Muzaffer
dc.contributor.authorDegirmenci, İrfan
dc.contributor.authorGüler, Halil İbrahim
dc.contributor.authorÜstüner, Cengiz
dc.contributor.authorMusmul, Ahmet
dc.date.accessioned2020-11-09T05:46:43Z
dc.date.available2020-11-09T05:46:43Z
dc.date.issued2014
dc.departmentAÇÜ, Sağlık Bilimleri Fakültesien_US
dc.description.abstractAim: The aim of this study was to investigate the polymorphism frequency of plasminogen activator inhibitor-1 (PAI-1) (rs1799889) 4G/5G in patients with lung cancer. Methods: In this study, 286 genomic DNAs (154 lung cancer patients + 132 subjects without lung cancer) were analyzed. Polymorphisms were determined by using the polymerase chain reaction (PCR) method, with 4G and 5G allele-specific primers. PCR products were assessed by a charge-coupled device camera and exposed to 2% agarose gel electrophoresis. Results: The frequencies of the PAI-1 gene 4G/5G genotypes were found to be 21% 4G/4G, 16% 4G/5G, and 62% 5G/5G in the control group and 31.4% 4G/4G, 30.8% 4G/5G, and 37.8% 5G/5G in the patient group. It was determined that the 5G/5G genotype frequency was high in patients in comparison with other genotypes. Conclusions: This study found a statistically significant difference between the groups with respect to genotype distribution. Consequently, we can say that the PAI-1 gene 4G/5G polymorphism is associated with lung cancer in Turkey.
dc.description.sponsorshipArtvin Coruh University: 2011.M80.02.01en_US
dc.identifier.citationBayramoglu, A., Gunes, H. V., Metintas, M., Degirmenci, I., Guler, H. I., Ustuner, C., & Musmul, A. (2014). Plasminogen activator inhibitor-1 and susceptibility to lung cancer: a population genetics perspective. Genetic testing and molecular biomarkers, 18(8), 587-590.en_US
dc.identifier.doi10.1089/gtmb.2014.0061
dc.identifier.endpage590en_US
dc.identifier.issue8en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage587en_US
dc.identifier.urihttps://hdl.handle.net/11494/2425
dc.identifier.volume18en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBayramoğlu, Ayşegül
dc.language.isoenen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.ispartofGenetic Testing and Molecular Biomarkers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords Available]en_US
dc.titlePlasminogen activator inhibitor-1 and susceptibility to lung cancer: a population genetics perspectiveen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
aysegul.bayramoglu.pdf
Boyut:
98.16 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Beslenme ve Diyetetik Bölümü Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu